Yuhui Huang Ph.D.

      

199 Ren'ai Rd. Suzhou, Jiangsu 215123, P.R.China

Cyrus Tang Hematology Center, Soochow University

Phone: 86-512-65880877-3507

Fax: 86-512-65880929

Email: huangyh@suda.edu.cn

 

 

 

 

Education:

1992-1996             B.S.,       Nanjing University

2000-2003             M.S.,      Shanghai Institutes for Biological Sciences (SIBS), CAS

2003-2007             Ph.D.,    Cancer Biology, Vanderbilt University, USA

2008-2013             Postdoctoral Fellow,    MGH/Harvard Medical School, USA

 

Professional Experience:

1996.07-2000.08       Research Associate,      LIVZON Pharmaceutical Group, China

2014.01-2014.06       Assistant Professor,       Mayo Clinic (Florida), USA

2014.07- Present      Professor,                       Soochow University, China

 

Research:

Despite the major advances in diagnosis and multimodal therapy, cancer remains the leading cause of death in the world. The recent breakthrough in cancer immunotherapies, such as ipilimumab (an anti-CTLA4 antibody), have demonstrated an impressive survival benefit in the treatment of advanced cancer patients and brought active immunotherapy into the limelight. However, cancer immunotherapy still faces many challenges. A critical one is the abnormal tumor microenvironment, which not only impede the delivery of anti-cancer agents, but also limit their effectiveness and induce drug resistance. My laboratory is dedicated to dissecting the molecular and cellular mechanisms in establishing an immunosuppressive tumor microenvironment and to exploring innovative strategies to recondition this environment. The ultimate goal is to translate gained knowledge to develop more selective and effective anti-cancer immunotherapies for cancer patients by integrating tumor immunology, vascular biology, biomarkers, Radiography and mathematical modeling.

 

Investigators:

 

       Recruiting…

 

Representative Publications:

 

1.      Zhang N#, Yin R#, Zhou P#, Liu X#, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X*, Wu D*, Huang Y*. DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression. Proc. Natl. Acad. Sci. U S A, 118 (22): e2020057118, 2021. 

2.      Zheng X#, Fang Z#, Liu X, Zhou P, Deng S, Wang X, Zhang C, Yin R, Hu H, Chen X, Zhao Y, Lin S, Qin S, Wang X, Kim B, Zhou P, Jiang W, Wu Q, Huang Y*. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J. Clin. Invest. 128(5): 2104-2115, 2018. 

3.    Huang Y*, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W*. Improving immune-vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 18(3): 195-203, 2018. 

4.    Zheng X, Zhang N, Qian L, Wang X, Fan P, Kuai J, Lin S, Liu C, Jiang W, Qin S, Chen H* and Huang Y*, CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils, Int. J. Cancer, 146(6):1730-1740, 2020. 

5.      Liu Y#, Song Y#, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao L, Teo KY, Qiu J, Jiang W, Dong C, Wu D*, Huang Y*, Liu H*. NCR group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine, 41:333-344, 2019.

6.    Deng S#, Zhang G#, Kuai J, Fan P, Wang X, Zhou P, Yang D, Zheng X, Liu X, Wu Q*, Huang Y*. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. J. Exp. Clin. Cancer Res. 37(1): 260, 2018. 

7.    Peterson TE#, Kirkpatrick ND#, Huang Y#, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D*, Jain RK*. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc. Natl. Acad. Sci. U S A 113(16): 4470-5, 2016. 

8.   Jiang W#, Huang Y#, An Y, Kim B*. Remodelling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano. 9(9): 8689-96, 2015. 

9.    Huang Y, Carbone DP*. Mechanisms of and Strategies for Overcoming Resistance to Anti-vascular Endothelial Growth Factor Therapy in Non-small Cell Lung Cancer. BBA Reviews on Cancer 1855(2):193-201, 2015. 

10.   Huang Y, Goel S, Duda DG, Fukumura D, Jain RK*. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73: 2943-8, 2013. 

11.   Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK*. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res. 73: 7144-6, 2013. 

12.   Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK*, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U S A 109: 17561-6, 2012.

13.  Huang Y, Snuderl M, Jain RK*. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19: 1-2, 2011. 

14.   Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP*. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res.71: 6122-31, 2011.

15.   Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP*. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110: 624-31, 2007. 

16.   Snuderl M#, Batista A#, Kirkpatrick ND#, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK*. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152: 1065-76, 2013. 

17.    Incio J, Ligibel JA, McManus DT, Suboj P, Pinter M, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari N, Roberge S, Wang D, Gomes-Santos I, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda D, Boucher Y, Fukumura D*, Jain RK*. Obesity promotes resistance to anti-VEGF therapy in breast cancer by upregulating IL-6 and FGF-2, Sci. Transl. Med. 10(432): eaag0945, 2018. 

18.   Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D*, Jain RK*. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov. 6(8): 852-869, 2016.